TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22796132
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg esomeprazole twice daily + aspirin placebo once daily (arm A; n = 30)
Study: 22796132
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg esomeprazole twice daily + 325 mg aspirin once daily (arm C; n = 45)
Study: 18559649
Drug: Artemisone 10
Normalized name: Artemisone
DrugBank: Artemisone (DB16097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisone 10 mg
Study: 18559649
Drug: Artemisone 20
Normalized name: Artemisone
DrugBank: Artemisone (DB16097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisone 20 mg
Study: 18559649
Drug: Artemisone 30
Normalized name: Artemisone
DrugBank: Artemisone (DB16097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisone 30 mg
Study: 18559649
Drug: Artemisone 40
Normalized name: Artemisone
DrugBank: Artemisone (DB16097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisone 40 mg (multiple doses for 3 days)
Study: 18559649
Drug: Artemisone 80
Normalized name: Artemisone
DrugBank: Artemisone (DB16097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisone 80 mg (multiple doses for 3 days)
Study: 15679068
Drug: Intravenous pamidronate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate, 3 mg/kg over 3 days every 4 months
Study: 15679068
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate 1 mg/kg, from a minimum of 10 mg to a maximum of 20 mg daily
Study: 12826145
Drug: Gengraf (generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gengraf (generic formulation of cyclosporine)
Study: 7573711
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 6 mg of DEC/kg of body weight at an interval of six months (group 2)
Study: 7573711
Drug: Community level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community level after group 1 treatment
Study: 29130624
Drug: Reduced bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced bleomycin dose (10,000 IU/m2)
Study: 29130624
Drug: Standard bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bleomycin dose (15,000 IU/m2)
Study: 10077706
Drug: Free supplementary
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free supplementary insurance for complementary medicine
Study: 7574745
Drug: Continuous arterial
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous arterial infusion of CDDP (10 mg/body) and 5-FU (250 mg/body) for 5 days, with 4 courses administered
Study: 7574745
Drug: Continuous arterial
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous arterial infusion of CDDP and 5-FU for 24 hours
Study: 2076713
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg daily)
Study: 31914241
Drug: Luspatercept (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luspatercept (1.0 up to 1.75 mg/kg, subcutaneously every 3 weeks)
Study: 19028953
Drug: Self-taken rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-taken rectal swabs for GC
Study: 19028953
Drug: Self-taken rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-taken rectal swabs for CT
Study: 19028953
Drug: Nurse-taken rectal
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-taken rectal swabs for CT
Study: 12816777
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dried peas and potatoes (meal 2)
Study: 10423609
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg quinapril once daily
Study: 10423609
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg captopril twice daily
Study: 1347260
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg d-1)
Study: 1347260
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg day-1)
Study: 1347260
Drug: Propranolol (80-480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80-480 mg)
Study: 30426896
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous and intraperitoneal chemotherapy
Study: 17617517
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy
Study: 23726933
Drug: Pragmatic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pragmatic intervention (n=49) including pharmaceutical management, multimodal physiotherapy, and psychology for post-traumatic stress.
Study: 11746330
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (specific treatment not mentioned)
Study: 11746330
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (specific treatment not mentioned)
Study: 30130421
Drug: No-CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-CPAP treatment
Study: 20236631
Drug: hMG+CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG+CC
Study: 7493311
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group D)
Study: 2058612
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 1.0 micrograms/kg/min for 72 hours
Study: 2058612
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 2.5 micrograms/kg/min for 72 hours
Study: 2058612
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (both doses)
Study: 6222636
Drug: FK 33-824
Normalized name: FK-960
DrugBank: FK-960 (DB06465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK 33-824 (2 mg)
Study: 23467551
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate in MLE cream
Study: 18670308
Drug: Larotaxel (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larotaxel (50 mg/m) + cisplatin (75 mg/m) every 3 weeks (arm A)
Study: 18670308
Drug: Larotaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larotaxel (60 mg/m) + gemcitabine (800 mg/m) every 3 weeks (arm B)
Study: 16756691
Drug: Bright-light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright-light therapy combined with sertraline
Study: 16756691
Drug: Dim-light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim-light therapy combined with sertraline
Study: 10994859
Drug: Dipyridamole 0.142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 0.142 mg/kg x min
Study: 8865952
Drug: 4-Methylpyrazole (4-MP)
Normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-Methylpyrazole (4-MP) at doses of 10 to 20 mg/kg
Study: 8865952
Drug: Ethanol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.6 g/kg followed by 0.2 g/kg twice)
Study: 9892329
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg warfarin
Study: 30518334
Drug: Oral Fosfomycin-Trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Fosfomycin-Trometamol 3000 mg (3 g every 24 h) for 10 days
Study: 30518334
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg every 12 h for 10 days (standard of care)
Study: 20697090
Drug: FC treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FC treatment arm
Study: 2272259
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyperthermia and radiation (RH)
Study: 2272259
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyperthermia and radiation (HR)
Study: 25646170
Drug: SRP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL
Study: 19284928
Drug: Olanzapine/Fluoxetine Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/Fluoxetine Combination (OFC)
Study: 373099
Drug: Bendrofluazide (thiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (thiazide diuretic)
Study: 27744438
Drug: Vaginal probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal probiotics with antibiotic prophylaxis
Study: 25931293
Drug: Antibiotics only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics only
Study: 19255890
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (1,260 mg eicosapentaenoic acid and 540 mg docosahexaenoic acid/day)
Study: 8546481
Drug: Three-pulse treatment
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-pulse treatment group (200 mg itraconazole twice daily for 1 week each month)
Study: 8546481
Drug: Four-pulse treatment
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-pulse treatment group (200 mg itraconazole twice daily for 1 week each month)
Study: 2063675
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (serum bilirubin < 12 mg/dl)
Study: 3914859
Drug: Ceftazidime (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (500 mg intravenously every 12 h)
Study: 3914859
Drug: Moxalactam (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (500 mg intravenously every 12 h; 2 g for Pseudomonas aeruginosa)
Study: 20423561
Drug: Anserine (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anserine (specific doses, intraperitoneal administration)
Study: 20423561
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of anserine
Study: 10512601
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for up to 8 weeks with ERT
Study: 10512601
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for up to 8 weeks without ERT
Study: 10512601
Drug: Fluoxetine responders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine responders treated up to 26 weeks
Study: 8744879
Drug: Physicians provided
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physicians provided with Hamilton Depression rating scale (HAM-D) scores and patient-specific treatment recommendations
Study: 25150954
Drug: Oral letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral letrozole (2.5mg/day) and norethindrone acetate (2.5mg/day) for three months prior to surgery (group A)
Study: 25150954
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment before surgery (group B)
Study: 21947680
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (28-day cycles: capecitabine 1,000 mg/m2 twice daily, days 1-5, 8-12, and 15-19; paclitaxel 80 mg/m2, days 1, 8, and 15)
Study: 15789590
Drug: Dose-Volume Histogram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-Volume Histogram (DVH)
Study: 15789590
Drug: Dose-Surface Histogram
Normalized name: sulfacetamide sodium Ophthalmic Solution [Sulfac]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-Surface Histogram (DSH)
Study: 12218390
Drug: Niacin, 3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin, 3000 mg/day for > or = 6 months
Study: 10485774
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (1 microg/kg)
Study: 1992574
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (total androgen blockade with nilutamide)
Study: 6606393
Drug: Moxalactam, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam, 250 mg every 12 h
Study: 6606393
Drug: Gentamicin, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin, 1 mg/kg every 8 h
Study: 26860641
Drug: Baseline creatinine
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline creatinine clearance <25 mL/min vs >65 mL/min
Study: 26860641
Drug: Discharge on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge on low-molecular-weight heparin
Study: 20433751
Drug: Phytotherapic compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytotherapic compound containing Pimpinella anisum, Foeniculum vulgare, Sambucus nigra, and Cassia augustifolia for 5 days
Study: 18608063
Drug: Moderate-intensity exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity exercise training (30 minutes of aerobic training followed by resistance training, twice weekly for six weeks)
Study: 16787138
Drug: PDE5 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDE5 inhibitors
Study: 12169865
Drug: L-threo-3,4-dihydroxyphenylserine (L-DOPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threo-3,4-dihydroxyphenylserine (L-DOPS) 400 mg
Study: 11961396
Drug: L-threo-3,4-dihydroxyphenylserine (L-DOPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threo-3,4-dihydroxyphenylserine (L-DOPS) 200 mg
Study: 7629406
Drug: naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone (0.4 mg/kg)
Study: 2393295
Drug: Amifloxacin 200
Normalized name: gatifloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifloxacin 200 mg q12h
Study: 2393295
Drug: Amifloxacin 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifloxacin 600 mg q12h
Study: 2393295
Drug: Amifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifloxacin 400 mg q8h
Study: 2393295
Drug: Amifloxacin 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifloxacin 600 mg q8h
Study: 2393295
Drug: Amifloxacin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifloxacin 800 mg q8h
Study: 2393295
Drug: Amifloxacin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifloxacin (all doses)
Study: 2393295
Drug: Amifloxacin (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifloxacin (doses above 1200 mg/day)
Study: 19496957
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (70 mg/kg magnesium sulphate infusions in 4 hours for 5 days)
Study: 19496957
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% solutions (control for blinding purposes)
Study: 20047115
Drug: Rosiglitazone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone plus metformin
Study: 16957566
Drug: Glyburide plus
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide plus metformin
Study: 3277398
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment of mild-to-moderate hypertension
Study: 11772140
Drug: Sustained-release oral
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release oral morphine
Study: 31124516
Drug: Retrobulbar block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar block with 0.5% ropivacaine plus dexmedetomidine 1 μg/kg (group RD, n = 20)
Study: 16709204
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms of oral misoprostol
Study: 3069206
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg daily for the first 3 months)
Study: 29494417
Drug: Monthly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly high-dose vitamin D3 (100,000 IU), n = 2041
Study: 29494417
Drug: Monthly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly high-dose vitamin D3 (100,000 IU) in vitamin D deficient participants (<50 nmol/L, 24.9%)
Study: 24942404
Drug: LY2603618 (≥240
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2603618 (≥240 mg) in combination with pemetrexed (500 mg/m²) and cisplatin (75 mg/m²)
Study: 24942404
Drug: LY2603618 (130-275
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2603618 (130-275 mg) in combination with pemetrexed (500 mg/m²) and cisplatin (75 mg/m²)
Study: 8617710
Drug: Haloperidol plus
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol plus sertraline (200 mg/day)
Study: 8500374
Drug: Preoperative short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative short-term high-dose irradiation (25.5 Gy in one week)
Study: 29704966
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) intervention, consisting of four 2.5-hour workshops over a 4-week period, with home exercises (e.g., meditation, observation grids)
Study: 23269680
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab plus ablative therapy
Study: 23269680
Drug: Ablative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative therapy alone
Study: 15758000
Drug: Clopidogrel (300-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300-mg loading dose, followed by 75 mg once daily)
Study: 1630347
Drug: Nebuhaler/MDI (metered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuhaler/MDI (metered dose aerosol terbutaline)
Study: 3934548
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum combined with behavioral treatment
Study: 10048102
Drug: 14 mg
Normalized name: iodine 0.14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg nicotine patches
Study: 18584466
Drug: placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patches
Study: 2210608
Drug: Cisapride 40
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride 40 mg (q.i.d.)
Study: 2210608
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg (b.i.d.)
Study: 2210608
Drug: Cimetidine 1600
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 1600 mg (q.i.d.)
Study: 2210608
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg (b.i.d.)
Study: 508701
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 500 mg/d
Study: 508701
Drug: Calcium caseinate
Normalized name: calcium caseinate
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium caseinate 15 g/d
Study: 31987544
Drug: Upper limb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper limb Robot‐assisted Therapy (RT)
Study: 31987544
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical Therapy (TT)
Study: 19302904
Drug: Compliance device
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Compliance device with grass allergen tablets
Study: 17391286
Drug: Simultaneous intervals
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous intervals for dose-finding trials
Study: 15492300
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (3 g at least 2 hours before the procedure and 2 g in the night and the morning after the procedure)
Study: 11235926
Drug: Olanzapine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5, 10, or 15 mg/day)
Study: 31939321
Drug: Cluster nursing
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster nursing measures in combination with continuous phototherapy (blue light)
Study: 28576897
Drug: FAB and
Normalized name: DIGOXIN IMMUNE FAB
DrugBank: Digoxin Immune Fab (Ovine) (DB00076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAB and combination groups (food, activity and breastfeeding intervention)
Study: 25942417
Drug: Gadolinium-based contrast
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium-based contrast agent (GBCA)
Study: 25942417
Drug: Non-gadolinium-based contrast
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-gadolinium-based contrast agent (non-GBCA)
Study: 21664710
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses (40-45Gy)
Study: 9170037
Drug: sprodiamide injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sprodiamide injection at 0.1 mmol/kg
Study: 9170037
Drug: sprodiamide injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sprodiamide injection at 0.2 mmol/kg
Study: 9170037
Drug: sprodiamide injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sprodiamide injection at 0.3 mmol/kg
Study: 9170037
Drug: sprodiamide injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sprodiamide injection at 0.1 mmol/kg at 2 ml/second
Study: 9170037
Drug: sprodiamide injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sprodiamide injection at 0.2 mmol/kg at 2 ml/second
Study: 9170037
Drug: sprodiamide injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sprodiamide injection at 0.3 mmol/kg at 2 ml/second
Study: 9170037
Drug: sprodiamide injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sprodiamide injection at 0.1 mmol/kg at 5 ml/second
Study: 9170037
Drug: sprodiamide injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sprodiamide injection at 0.2 mmol/kg at 5 ml/second